Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 514

1.

The Interleukin-20 Cytokine Family in Liver Disease.

Caparrós E, Francés R.

Front Immunol. 2018 May 28;9:1155. doi: 10.3389/fimmu.2018.01155. eCollection 2018. Review.

2.

Gemcabene downregulates inflammatory, lipid-altering and cell-signaling genes in the STAM™ model of NASH.

Oniciu DC, Hashiguchi T, Shibazaki Y, Bisgaier CL.

PLoS One. 2018 May 30;13(5):e0194568. doi: 10.1371/journal.pone.0194568. eCollection 2018.

3.

First right lobe living-donor hepatectomy after sleeve gastrectomy.

Obed A, Bashir A, Jarrad A.

BMC Surg. 2018 May 29;18(1):31. doi: 10.1186/s12893-018-0366-7.

4.

Is de novo hepatocellular carcinoma after transjugular intrahepatic portosystemic shunt increased?

Hüsing-Kabar A, Meister T, Köhler M, Domschke W, Kabar I, Wilms C, Hild B, Schmidt HH, Heinzow HS.

United European Gastroenterol J. 2018 Apr;6(3):413-421. doi: 10.1177/2050640617732886. Epub 2017 Sep 20.

5.

Mortality Associated with Hepatobiliary Disease in Portugal between 2006 and 2012.

da Rocha MC, Marinho RT, Rodrigues T.

GE Port J Gastroenterol. 2018 Apr;25(3):123-131. doi: 10.1159/000484868. Epub 2017 Dec 6.

6.

The Burden of Hepatobiliary Diseases in Portugal: What Can We Learn from Mortality Data.

Simão A.

GE Port J Gastroenterol. 2018 Apr;25(3):110-111. doi: 10.1159/000484094. Epub 2017 Dec 8. No abstract available.

7.

Higher risk of hepatocellular carcinoma in Hispanic patients with hepatitis C cirrhosis and metabolic risk factors.

Wong A, Le A, Lee MH, Lin YJ, Nguyen P, Trinh S, Dang H, Nguyen MH.

Sci Rep. 2018 May 8;8(1):7164. doi: 10.1038/s41598-018-25533-2.

8.

Nonalcoholic fatty liver disease: epidemiology, pathogenesis and therapeutic implications.

Andronescu CI, Purcarea MR, Babes PA.

J Med Life. 2018 Jan-Mar;11(1):20-23. Review.

9.

miR-203 Inhibits Alcohol-Induced Hepatic Steatosis by Targeting Lipin1.

Cheng XY, Liu JD, Lu XY, Yan X, Huang C, Meng XM, Li J.

Front Pharmacol. 2018 Apr 4;9:275. doi: 10.3389/fphar.2018.00275. eCollection 2018.

10.

The Biological Clock: A Pivotal Hub in Non-alcoholic Fatty Liver Disease Pathogenesis.

Mazzoccoli G, De Cosmo S, Mazza T.

Front Physiol. 2018 Mar 15;9:193. doi: 10.3389/fphys.2018.00193. eCollection 2018. Review.

11.

Metabolomics: From liver chiromancy to personalized precision medicine in advanced chronic liver disease.

Procopet B, Fischer P, Farcau O, Stefanescu H.

World J Hepatol. 2018 Mar 27;10(3):371-378. doi: 10.4254/wjh.v10.i3.371. Review.

12.

p53 as a Dichotomous Regulator of Liver Disease: The Dose Makes the Medicine.

Krstic J, Galhuber M, Schulz TJ, Schupp M, Prokesch A.

Int J Mol Sci. 2018 Mar 20;19(3). pii: E921. doi: 10.3390/ijms19030921. Review.

13.

Copper/MYC/CTR1 interplay: a dangerous relationship in hepatocellular carcinoma.

Porcu C, Antonucci L, Barbaro B, Illi B, Nasi S, Martini M, Licata A, Miele L, Grieco A, Balsano C.

Oncotarget. 2018 Jan 20;9(10):9325-9343. doi: 10.18632/oncotarget.24282. eCollection 2018 Feb 6.

14.

Serum Iron Levels Decreased in Patients with HBV-Related Hepatocellular Carcinoma, as a Risk Factor for the Prognosis of HBV-Related HCC.

Wei Y, Ye W, Zhao W.

Front Physiol. 2018 Feb 6;9:66. doi: 10.3389/fphys.2018.00066. eCollection 2018.

15.

Liver Transplantation for Alcoholic Liver Disease and Hepatocellular Carcinoma.

Burra P, Zanetto A, Germani G.

Cancers (Basel). 2018 Feb 9;10(2). pii: E46. doi: 10.3390/cancers10020046. Review.

16.

Role of gut microbiota and oxidative stress in the progression of non-alcoholic fatty liver disease to hepatocarcinoma: Current and innovative therapeutic approaches.

Borrelli A, Bonelli P, Tuccillo FM, Goldfine ID, Evans JL, Buonaguro FM, Mancini A.

Redox Biol. 2018 May;15:467-479. doi: 10.1016/j.redox.2018.01.009. Epub 2018 Feb 3. Review.

17.

Recent trends in liver transplantation for alcoholic liver disease in the United States.

Kling CE, Perkins JD, Carithers RL, Donovan DM, Sibulesky L.

World J Hepatol. 2017 Dec 28;9(36):1315-1321. doi: 10.4254/wjh.v9.i36.1315.

18.

Epidemic of non-alcoholic fatty liver disease and hepatocellular carcinoma.

Said A, Ghufran A.

World J Clin Oncol. 2017 Dec 10;8(6):429-436. doi: 10.5306/wjco.v8.i6.429. Review.

19.

Interaction and joint effect of ALT and chronic liver disease on liver cancer in type 2 diabetes patients.

Li TC, Li CI, Liu CS, Lin PH, Lin WY, Lin CH, Yang SY, Chiang JH, Lin CC.

Oncotarget. 2017 Oct 10;8(61):103851-103863. doi: 10.18632/oncotarget.21804. eCollection 2017 Nov 28.

20.

A rare presentation of hepatocellular carcinoma in non-cirrhotic liver.

Kabbage L, El Kouhen M, Taghy A, Znati K, Kabbaj N.

Pan Afr Med J. 2017 Sep 22;28:69. doi: 10.11604/pamj.2017.28.69.13512. eCollection 2017.

Supplemental Content

Loading ...
Support Center